Retrospective estimate of the quality of intensity-modulated radiotherapy plans for lung cancer

Jihye Koo, Myonggeun Yoon, Weon Kuu Chung, Dong Wook Kim

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


This study estimated the planning quality of intensity-modulated radiotherapy in 42 lung cancer cases to provide preliminary data for the development of a planning quality assurance algorithm. Organs in or near the thoracic cavity (ipsilateral lung, contralateral lung, heart, liver, esophagus, spinal cord, and bronchus) were selected as organs at risk (OARs). Radiotherapy plans were compared by using the conformity index (CI), coverage index (CVI), and homogeneity index (HI) of the planning target volume (PTV), the OAR-PTV distance and the OAR-PTV overlap volume, and the V10Gy, V20Gy, and equivalent uniform dose (EUD) of the OARs. The CI, CVI, and HI of the PTV were 0.54–0.89 (0.77 ± 0.08), 0.90–1.00 (0.98 ± 0.02), and 0.11–0.41, (0.15 ± 0.05), respectively. The mean EUDs (V10Gy, V20Gy) of the ipsilateral lung, contralateral lung, esophagus, cord, liver, heart, and bronchus were 8.07 Gy (28.06, 13.17), 2.59 Gy (6.53, 1.18), 7.02 Gy (26.17, 12.32), 3.56 Gy (13.56, 4.48), 0.72 Gy (2.15, 0.91), 5.14 Gy (19.68, 8.62), and 10.56 Gy (36.08, 19.79), respectively. EUDs tended to decrease as the OAR-PTV distance increased and the OAR-PTV overlap volume decreased. Because the plans in this study were from a single department, relatively few people were involved in treatment planning. Differences in treatment results for a given patient would be much more pronounced if many departments were involved.

Original languageEnglish
Pages (from-to)136-141
Number of pages6
JournalJournal of the Korean Physical Society
Issue number1
Publication statusPublished - 2015 Jul 31


  • Dose-volume histogram
  • Dosimetry
  • Lung cancer
  • Planning quality
  • Quality assurance

ASJC Scopus subject areas

  • Physics and Astronomy(all)


Dive into the research topics of 'Retrospective estimate of the quality of intensity-modulated radiotherapy plans for lung cancer'. Together they form a unique fingerprint.

Cite this